Chemours Co.

Chemours, together with DuPont de Nemours and Corteva, agreed to a $455 million settlement with North Carolina and eleven municipalities to resolve PFAS lawsuits. Chemours’ 50% share has a present value of about $180 million and is covered by existing reserves. In addition, a $50 million trust payment that would have been due in September 2026 is no longer required, and the company filed a Form 8-K with the SEC. The news drove a premarket rally in the stock and reduced perceived risk for investors. » More on de.investing.com

Chemours is launching the refrigerants Opteon ZE (R-1234ze(E)) and Opteon 515B (a blend of R-1234ze(E) and R-227ea), developed for stationary chillers in data centers and commercial buildings. Opteon ZE is an HFO with a GWP of about 1 and ASHRAE safety class A2L; Opteon 515B has a GWP of around 293 and safety class A1. The company emphasizes efficiency, reliability and regulatory compliance, and is offering the products immediately in strategic countries with planned expansion depending on demand. » More on de.investing.com

The board of directors of Chemours has approved a cash dividend of $0.0875 per common share for the third quarter of 2026. The payment date is September 15, 2026; shareholders of record at the close of trading on August 14, 2026 are eligible. Chemours is a manufacturer of industrial and specialty chemicals headquartered in Wilmington, Delaware, and operates 28 production sites. » More on de.investing.com

A coalition of 17 environmental groups urged the EPA to reject Chemours’ application to fast-track Opteon 2P50 for datacentre cooling, saying the company downplays the compound’s toxicity and climate impacts. The groups allege flawed science and missing toxicological data in Chemours’ submission, including reliance on an industry-linked committee and rat studies that understate human risk. They warn approval could increase PFAS pollution, enable wider industrial and consumer use, and prompt legal challenges if the EPA sidesteps statutory health-risk assessments. » More on theguardian.com

Options trading volume for Chemours reached 5,376 contracts on Thursday, comprising 4,348 calls and 1,028 puts, according to Bloomberg data. Notable were calls expiring July 24, 2026 (strike $22) with 2,619 contracts and calls expiring July 17, 2026 (strike $20) with 1,210 contracts. The stock fell 5.21% to $19.09; three‑month volatility fell to 66.87% and the three‑month skew (90/110) rose to -0.58 percentage points. Open interest figures are as of July 1. » More on de.investing.com